Results 21 to 30 of about 29,386 (262)

Natural outer membrane permeabilizers boost antibiotic action against irradiated resistant bacteria

Journal of Biomedical Science, 2019
Background This study sought to develop new strategies for reverting the resistance of pathogenic Gram-negative bacilli by a combination of conventional antibiotics, potent permeabilizers and natural beta lactamase inhibitors enhancing the activity of ...
Hala A. Farrag, Nagwa Abdallah, Mona M. K. Shehata, Ebthag M. Awad   +3 more
doaj   +1 more source

Clinical Evolution of New Delhi Metallo-β-Lactamase (NDM) optimizes resistance under Zn(II) Deprivation [PDF]

, 2018
Carbapenem-resistant Enterobacteriaceae (CRE) are rapidly spreading and taking a staggering toll on all health care systems, largely due to the dissemination of genes coding for potent carbapenemases.
Bahr, Guillermo, Bethel, Christopher R., Bonomo, Robert A., Gonzalez, Lisandro Javier, Vila, Alejandro Jose, Vitor Horen, Luisina   +5 more
core   +1 more source

Effect of pH on activities of novel beta-lactamases and beta-lactamase inhibitors against these beta-lactamases [PDF]

Antimicrobial Agents and Chemotherapy, 1995
The effects of acidic conditions on activities of seven beta-lactamases--TEM-1 (class A), KOXY (class A), IMP-1 (class B), AmpC (class C), MOX-1 (class C), OXA-5 (class D), and PSE-2 (class D)--and their inhibitors were measured. The enzymatic activities of KOXY, IMP-1, and MOX-1 at pH 5.8 were slightly lower than those at pH 7.5.
S, Ohsuka, Y, Arakawa, T, Horii, H, Ito, M, Ohta   +4 more
openaire   +2 more sources

Multiparametric determination of genes and their point mutations for identification of beta-lactamases [PDF]

, 2010
More than half of all currently used antibiotics belong to the beta-lactam group, but their clinical effectiveness is severely limited by antibiotic resistance of microorganisms that are the causative agents of infectious diseases. Several mechanisms for
A. A. Medeiros, A. Bauernfield, A. J. Brookes, A. M. Egorov, A. Nikulin, A. Philippon, A. Tamilselvi, A. Yu. Rubina, B. E. E. Cleven, B. Strommenger, C. C. Randegger, C. D. Steward, C. Heritier, C. Heritier, C. I. Birkett, C. Mabilat, C. Mugnaioli, D. E. Mudrak, D. Gryadunov, D. L. Paterson, D. L. Paterson, D. L. Paterson, D. M. Leinberger, D. M. Livermore, D. M. Livermore, D. M. Livermore, D. M. Livermore, D. M. Livermore, D. Szabo, D. V. Ivanov, E. B. Chaibi, E. M. Southern, F. Hayes, F. J. L. Robberts, F. Perez, F.-H. M’Zali, G. F. Weldhagen, H. C. Maltezou, H. F. Chambers, H. J. Monstein, H. Knothe, H. Wang, I. Massova, I. Rodriguez, I. Weigand, I. Wiegand, J. D. D. Pitout, J. D. D. Pitout, J. D. Pitout, J. D. Pitout, J. Empel, J. F. Petrosino, J. L. Jones, J. M. Ghuysen, J. Rodriguez-Bano, J. Schlesinger, J. Schmitt, J. W. Schumm, K. Bush, K. Bush, K. Bush, L. Bodrossy, L. Drieux, L. N. Ikryannikova, L. Pagani, L. Poirel, L. Poirel, L. S. Tzouvelekis, L. X. Zhu, L. Xu, L. Xu, M. Babic, M. Batchelor, M. Cassone, M. Chee, M. Edelstein, M. F. Lartigue, M. Guckenberger, M. H. Richmond, M. I. Page, M. J. Heller, M. J. Schwaber, M. J. Schwaber, M. M. Ulyashova, M. M. Ulyashova, M. Nukaga, M. Ozsoz, M. Quinteros, M. R. Mulvey, M. Schena, M. Shogo, M. Yu. Rubtsova, N. C. Strynadka, N. Datta, N. Shibata, N. Woodford, N. Woodford, P. A. James, P. Bradford, P. C. Fleming, P. M. Hawkey, R. Alonso, R. B. Sykes, R. Bonnet, R. Bonnet, R. Canton, R. D. Schmid, R. P. Ambler, S. Chen, S. Egorova, S. Harada, S. K. Du Bois, S. Kalai Blagui, S. V. Sidorenko, S. V. Sidorenko, T. L. Wu, T. Naas, T. R. Hughes, T. T. Bachmann, V. A. Doss, V. Chizhikov, V. Grimm, V. M. Ensor, V. Perreten, X. Cao, X. Yu, Y. Lee, Y. Michikawa   +127 more
core   +1 more source

Fecal Microbiota Transplant in Cirrhosis Reduces Gut Microbial Antibiotic Resistance Genes: Analysis of Two Trials

Hepatology Communications, 2021
Antibiotic resistance leads to poor outcomes in cirrhosis. Fecal microbiota transplant (FMT) is associated with reduction in antibiotic resistance gene (ARG) burden in patients without cirrhosis; however, the impact in cirrhosis is unclear.
Jasmohan S. Bajaj, Amirhossein Shamsaddini, Andrew Fagan, Richard K. Sterling, Edith Gavis, Alexander Khoruts, Michael Fuchs, Hannah Lee, Masoumeh Sikaroodi, Patrick M. Gillevet   +9 more
doaj   +1 more source

Identification of drivers of mycobacterial resistance to peptidoglycan synthesis inhibitors

Frontiers in Microbiology, 2022
Beta-lactams have been excluded from tuberculosis therapy due to the intrinsic resistance of Mycobacterium tuberculosis (Mtb) to this antibiotic class, usually attributed to a potent beta-lactamase, BlaC, and to an unusually complex cell wall.
Francisco Olivença, Cláudia Ferreira, Alexandra Nunes, Alexandra Nunes, Cátia Silveiro, Madalena Pimentel, João Paulo Gomes, João Paulo Gomes, Maria João Catalão   +8 more
doaj   +1 more source

The reaction mechanism of metallo-beta-lactamases is tuned by the conformation of an active site mobile loop [PDF]

, 2018
Carbapenems are "last resort" β-lactam antibiotics used to treat serious and life-threatening health care-associated infections caused by multidrug-resistant Gram-negative bacteria.
Alzari, Pedro M., Bethel, Christopher R., Bonomo, Robert A., Giannini, Estefanía, Klinke, Sebastian, Llarrull, Leticia Irene, Mojica, María F., Otero, Lisandro Horacio, Palacios, Antonela Rocio, Taracila, Magdalena A., Vila, Alejandro Jose   +10 more
core   +1 more source

Involvement of a Novel Class C Beta-Lactamase in the Transglutaminase Mediated Cross-Linking Cascade of Streptomyces mobaraensis DSM 40847. [PDF]

PLoS ONE, 2016
Streptomyces mobaraensis DSM 40847 secretes transglutaminase that cross-links proteins via γ-glutamyl-ε-lysine isopeptide bonds. Characterized substrates are inhibitory proteins acting against various serine, cysteine and metalloproteases. In the present
Stephan Zindel, Vera Ehret, Marina Ehret, Madeleine Hentschel, Samantha Witt, Andreas Krämer, David Fiebig, Norbert Jüttner, Sabrina Fröls, Felicitas Pfeifer, Hans-Lothar Fuchsbauer   +10 more
doaj   +1 more source

Antimicrobial use in European acute care hospitals: results from the second point prevalence survey (PPS) of healthcare-associated infections and antimicrobial use, 2016 to 2017 [PDF]

, 2018
Antimicrobial agents used to treat infections are life-saving. Overuse may result in more frequent adverse effects and emergence of multidrug-resistant microorganisms.
Aghdassi, S., Alberg, T., Arendt, V., Arvaniti, K., Asensio, A., Berg, T. C., Berger-Carbonne, A., Borg, M. A., Bosnjak, Z., Budimir, A., Burns, K., Cairns, S., Cantero, M., Daniau, C., Debacker, M., Deptula, A., Dimina, E., Dobreva, E., Dragovac, G., Florentin, D., Gastmeier, P., Gibbons, C., Gudlaugsson, O., Hadjihannas, L., Hajdu, A., Hansen, S., Harrison, W., Hopkins, S., Hopmans, T., Hristova, R., Ivanov, I. N., Jindrak, V., Johnson, A., Karki, T., Kinross, P., Kontopidou, F., Korosec, A., Latour, K., Litvova, S., Lyytikainen, O., Markovic-Denic, L., Martin, P., McConaghy, M., Mitt, P., Monnet, D. L., Moro, M. L., Nedyalkov, M., Neves, I., Niculcea, A. S., Pacheco, P., Plachouras, D., Presterl, E., Quattrocolo, F., Reilly, J., Rydygier, L., Sartaj, M., Sarvikivi, E., Serban, R. I., Smid, E., Staniulyte, J., Stefkovicova, M., Strauss, R., Suetens, C., Vandael, E., Vilde, A., Weist, K., Zarb, P., Zingg, W., Zotti, C. M., Zupanc, T. L.   +69 more
core   +7 more sources

Inhibitor resistant class A beta-lactamases [PDF]

Frontiers in Bioscience, 1999
Beta-lactamase inhibitors (clavulanic acid, tazobactam, and sulbactam) greatly enhance the therapeutic efficacy of their partner antibiotics (amoxacillin, ampicillin, piperacillin, and ticarcillin) against common enteric and non-enteric organisms possessing class A beta-lactamases.
R A, Bonomo, L B, Rice
openaire   +2 more sources